Singapore, April 18 -- Collaborative Medicinal Development LLC (CMD) is a privately-held biopharmaceutical company developing innovative therapies for neurodegenerative diseases. CMD has announced that it was awarded a AU$1 million grant from FightMND to support a Phase 2 study of CuATSM for treatment ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig'sdisease, or Motor Neuron Disease (MND).

In 2016, FightMND helped to support the phase 1 clinical trial of CuATSM where it was given to MND patients as a therapeutic for the first time. The primary objective, as per any phase 1 trial, was to assess safety and tolerability of the drug and, if possible, identify a dose that could be taken to the next round of testing. By assessing ...